The prenatal testing and newborn screening tests market consists of sales of prenatal testing and newborn screening tests services and related goods by entities (organizations, sole traders and partnerships) that provide prenatal testing and newborn screening tests, which help to determine various genetic and chromosomal diseases, to provide timely medical or surgical treatment of a condition before or after birth. Genetic diseases such as sickle cell, down’s syndrome, cystic fibrosis and muscular dystrophy are detected with the help of these tests. Only goods and services traded between entities or sold to end consumers are included.
The global prenatal testing and newborn screening market is expected to decline from $4.39 billion in 2019 to $4.18 billion in 2020 at a compound annual growth rate (CAGR) of -4.79%. The decline is mainly due to the COVID-19 outbreak that has led to deferred care in order to avoid visiting hospitals, which resulted in reduced patient volume. The market is then expected to recover and reach $6.04 billion in 2023 at a CAGR of 13.09%.
